Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected AdolescentsPatricia M. Flynn, Magda Opsomer, Svitlana Komar et al.|The Pediatric Infectious Disease Journal|2014Cited by 28
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD TrialsErkki Lathouwers, Renato Maserati, Anne Ghys et al.|AIDS Research and Human Retroviruses|2019Cited by 14